site stats

Thor-707 sitc

WebOct 1, 2024 · THOR-707 is a reprogrammed, site-directed, single pegylated, recombinant human IL-2 (rIL-2) variant that lacks binding affinity for the α chain of the IL-2 receptor. Because THOR-707 has near-native binding affinity for the βγ chain of the IL-2 receptor, it produces an immune-active, CD8+ T effector-driven anti-tumor effect. WebOct 1, 2024 · While this is a reasonable strategy to avoid off-tumor side effects, clinical benefit has been seen with multiple untargeted IL-2 variant molecules such as NKTR-214, THOR-707, and ALKS-4230 23, 24 ...

Pegenzileukin - Sanofi - AdisInsight - Springer

WebApr 4, 2024 · Latest Information Update: 21 Nov 2024. Price : $50 *. Buy Profile. Adis is an information provider. We do not sell or distribute actual drugs. Final gross price and currency may vary according to local VAT and billing address. Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. WebOct 29, 2024 · Part 1 of the study will determine the recommended phase 2 dose (RP2D) of THOR-707 as a single agent and part 2 will determine the RP2D of THOR-707 in combination with a PD-1 inhibitor. nethertown railway station https://sttheresa-ashburn.com

Preliminary results from an open-label, multicenter ... - ResearchGate

WebJun 3, 2024 · SAR444245 (formerly known as THOR-707), Sanofi’s product candidate, is a differentiated IL-2 engineered for specificity and selectivity towards CD8+ T cells and Natural Killer (NK) cells. The molecule has a single, targeted PEG-moiety irreversibly linked to a novel amino acid inserted at a precise location. WebTHOR 707 - THOR-707, a “not-alpha†Synthorinâ„¢ of interleukin-2 (IL-2), for the treatment of solid tumors at the Society for Immunotherapy of Cancer (SITC) THOR-707, … WebSITC 2024 is the leading destination for scientific exchange, education and networking in the cancer immunotherapy field. ... Open-Label, Multicenter Phase 1/2 Dose Escalation and … i\u0027ll get right on that meme

A Study Evaluating Safety and Therapeutic Activity of THOR-707 in …

Category:481 Phase 1/2 study of THOR-707 (SAR444245), a pegylated recombin…

Tags:Thor-707 sitc

Thor-707 sitc

THOR 707 - Uses, DMF, Dossier, Manufacturer, Supplier, Licensing ...

WebJul 5, 2024 · THOR-707 Q3W at recommended Phase 2 dose (RP2D) with a checkpoint inhibitor via IV administration Q6W will consist of one 9-week cycle of THOR monotherapy … WebOct 29, 2024 · THOR-707 is currently being evaluated by Sanofi in an ongoing Phase 1 open-label, multi-center, dose escalation and expansion trial. This study is designed to evaluate …

Thor-707 sitc

Did you know?

WebOct 29, 2024 · Part 1 of the study will determine the recommended phase 2 dose (RP2D) of THOR-707 as a single agent and part 2 will determine the RP2D of THOR-707 in combination with a PD-1 inhibitor. WebNov 9, 2024 · Synthorx Inc. announced that company researchers will present results of preclinical studies demonstrating the safety and anti-tumor effects of its lead product candidate THOR-707, a Synthorin of... March 12, 2024

WebApr 10, 2024 · Two of those occurred in combination with Merck & Co’s Keytruda, so their relevance is debatable, especially as one was in a PD-(L)1 therapy-naive subject. Thus investor focus should be on the remaining remission, in a third-line squamous cell carcinoma patient on Thor-707 monotherapy who experienced 31% tumour shrinkage. Cytokine focus WebLighting up only the immune cells that matter Asher Bio

WebJun 27, 2024 · THOR-707 Q3W at recommended Phase 2 dose (RP2D) with a checkpoint inhibitor via IV administration Q6W will consist of one 9-week cycle of THOR monotherapy on Cycle 1 Day 1 followed by THOR-707 Q3W + checkpoint inhibitor at Cycle 1 Day 22. Subsequently treatment will consist of repeated 6-weeks cycles with combination therapy. WebSITC 2024 (Poster) - Phase 1/2 study of THOR-707 (SAR444245), ... AACR 2024 (Late-Breaking, Poster) - [VIRTUAL] THOR-707 (SAR444245), a novel not-alpha IL-2 as …

WebJul 5, 2024 · THOR-707 Q3W at recommended Phase 2 dose (RP2D) with a checkpoint inhibitor via IV administration Q6W will consist of one 9-week cycle of THOR monotherapy on Cycle 1 Day 1 followed by THOR-707 Q3W + checkpoint inhibitor at Cycle 1 Day 22. Subsequently treatment will consist of repeated 6-weeks cycles with combination therapy.

WebBackground SAR444245 (THOR-707) is a recombinant human IL-2 molecule that includes a PEG moiety irreversibly bound to a novel amino acid via click chemistry to block the alpha … i\u0027ll get right on it 意味WebJun 7, 2024 · A Phase 2 Non-randomized, Open-label, Multi-cohort, Multi-center Study Assessing the Clinical Benefit of SAR444245 (THOR-707) Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Pleural Mesothelioma: Actual Study Start Date : September 23, 2024: Estimated Primary Completion Date : July … nether townshipWebOpen-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and in Combination with a PD-1 Inhibitor in Adult Subjects with Advanced or … i\u0027ll get right on top of that roseWebAug 9, 2024 · The THOR-707 volume of distribution at steady state (Vss; 82.4 mL/kg) was about 4.7-fold reduced relative to aldesleukin and similar to the blood volume for mice 17 … nethertown surgery fifeWebJul 1, 2024 · Abstract. THOR-707 (SAR444245) is a recombinant human IL-2 molecule that includes a PEG moiety irreversibly bound to a novel amino acid via click chemistry to … nethertown surgery facebookWebSanofi bet big on engineered IL-2 in 2024, dropping $2.5 billion to acquire Synthorx and its lead program, THOR-707. Now, the French pharma is reporting early phase 1 data showing the treatment ... i\u0027ll get straight to the pointWebNov 1, 2024 · Background THOR-707 (SAR444245) is a recombinant human IL-2 molecule irreversibly bound to a PEG chain to block alpha-binding while retaining near-native affinity … nethertown surgery dunfermline fife